Nanocarbontech Spółka z Ograniczoną Odpowiedzialnością (KRS 0001034140, NIP 9721339236) is a Polish company, headquartered in Poznań, Wielkopolskie voivodeship. Nanocarbontech operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since May 4, 2023. Nanocarbontech's most recently reported net revenue was 24.0 K PLN for 2024.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Nanocarbontech
Identity
- Name
- Nanocarbontech Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- May 4, 2023
- Registry status as of
- January 14, 2026
- Latest entry
- January 13, 2026
- Founding act
- 28.04.2023
Articles of association history (2)
- April 28, 2023: 28.04.2023
- May 20, 2024: 20.05.2024 R., ZMIANA § 4
Activities
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. RUBIEŻ, 46, 61-612, POZNAŃ, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- POZNAŃ
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-94012-26290-JUTTD-27
- Coordinates
- 52.4079, 16.9335approx.
Risk and payment profile - Nanocarbontech
Credibility rating
71.3 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
4
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/3 yrs
Board changes
0
0/3 yrs
PKD changes
0
0/3 yrs
Name changes
0
0/3 yrs
Data from 3 years of registry activity.
Credibility history
Payment reliability score from 2023–2024
Current: B (71/100)
Trend: improving (+30.0 pts/year)
High payment credibility - the company's financial condition is good and the risk of cooperating with it is low.
Trade credit limit history
Standard limit from 2023–2024
Current: 5.8 K PLN
Safe: 3.8 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Nanocarbontech
Founded
May 4, 2023
3 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
POZNAŃ
WIELKOPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
100 shares total
Shareholders
3
shareholders
Board
1 person
Filed years
2 years
2023–2024 · profitable: 1/2
Registry entries
8
latest: January 13, 2026
Revenue
24.0 K PLN
2024
Net profit
11.4 K PLN
2024
Assets
26.6 K PLN
2024
Equity
14.1 K PLN
2024
EBITDA
N/A
2024
no depreciation data
Valuation
56.2 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Nanocarbontech.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
